TempTraq

DEVICE3 trials

Sponsors

The Cleveland Clinic, Duke University, National Cancer Institute (NCI)

Conditions

Antibodies BispecificBody TemperatureCell and Tissue-Based TherapyCytokine Release SyndromeCytokinesHematologic MalignancyImmune MonitoringImmunotherapy

Unknown Phase

Accuracy and Precision Comparison of Temptraq

CompletedNCT03264833

The Cleveland ClinicTemperature

Start: 2016-12-15End: 2017-10-01Updated: 2026-02-12

VitalTraq for the Detection of CRS

CompletedNCT06415656

Duke UniversityHematologic Malignancy

Start: 2024-10-13End: 2025-07-07Updated: 2026-07-15

Continuous Temperature Monitoring (CTM) for Cytokine Release Syndrome (CRS), an Immune-Related Adverse Event

Enrolling by invitationNCT07499128

National Cancer Institute (NCI)Antibodies Bispecific, Body Temperature, Cell and Tissue-Based Therapy +13

Start: 2026-05-27End: 2029-08-18Target: 136Updated: 2026-06-25

Related Papers

Remote multi-vital sign monitoring allows earlier detection of cytokine release syndrome after bispecific T cell engager and chimeric antigen receptor T cell therapies

Blood2025-11-03